Bluebird Net Debt from 2010 to 2024

BLUE Stock

USD 0.74 0.38 104.53%

Bluebird Bio's Net Debt is increasing over the years with slightly volatile fluctuation. Overall, Net Debt is expected to go to about 203.3 M this year. Net Debt is the total debt of Bluebird bio minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2012-12-31

Previous Quarter

246.4 M

Current Value

297.8 M

Quarterly Volatility

251.1 M

Yuan Drop

Covid

Check Bluebird Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bluebird Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 31.6 M or Selling General Administrative of 126.8 M, as well as many indicators such as Price To Sales Ratio of 4.88, Dividend Yield of 0.0 or PTB Ratio of 0.46. Bluebird financial statements analysis is a perfect complement when working with Bluebird Bio Valuation or Volatility modules.

Check out the analysis of Bluebird Bio Correlation against competitors.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

Latest Bluebird Bio's Net Debt Growth Pattern

Below is the plot of the Net Debt of Bluebird bio over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Bluebird Bio's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bluebird Bio's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Bluebird Net Debt Regression Statistics

	Arithmetic Mean	(103,409,115)
	Geometric Mean	131,624,888
	Coefficient Of Variation	(202.80)
	Mean Deviation	146,727,893
	Median	(102,368,000)
	Standard Deviation	209,714,209
	Sample Variance	43980T
	Range	806M
	R-Value	0.39
	Mean Square Error	40086.8T
	R-Squared	0.15
	Significance	0.15
	Slope	18,380,108
	Total Sum of Squares	615720.7T

Bluebird Net Debt History

	2024	203.3 M
	2023	193.6 M
	2022	168.4 M
	2021	-71.6 M
	2020	-124.7 M
	2019	-136.2 M
	2018	-247.8 M

Other Fundumenentals of Bluebird bio

Net Debt To E B I T D A

Bluebird Bio Net Debt component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Receivables	Good Will	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.56	-0.42	-0.24	0.56	0.92	0.69	0.95	-0.07	0.45	0.52	0.94	0.7	0.31	0.84	0.55	-0.32	0.51	0.75	0.64	0.64	0.14	0.1	-0.1
Total Stockholder Equity	0.96		0.67	-0.61	-0.02	0.45	0.95	0.55	0.98	-0.29	0.24	0.3	0.99	0.59	0.09	0.83	0.41	-0.32	0.54	0.84	0.5	0.51	0.35	0.31	-0.25
Current Deferred Revenue	0.56	0.67		-0.78	0.29	0.14	0.57	0.06	0.68	-0.48	-0.05	-0.06	0.65	0.08	-0.19	0.5	-0.01	-0.46	0.41	0.52	0.07	0.09	0.51	0.47	-0.35
Net Debt	-0.42	-0.61	-0.78		-0.57	0.08	-0.47	0.2	-0.65	0.71	0.37	0.36	-0.62	0.06	0.54	-0.44	0.25	0.25	-0.41	-0.55	0.12	0.1	-0.7	-0.7	0.58
Retained Earnings	-0.24	-0.02	0.29	-0.57		-0.61	-0.03	-0.74	-0.04	-0.79	-0.92	-0.81	0.04	-0.74	-0.77	-0.13	-0.89	0.37	0.07	0.19	-0.82	-0.8	0.91	0.92	-0.67
Accounts Payable	0.56	0.45	0.14	0.08	-0.61		0.51	0.76	0.46	0.31	0.6	0.49	0.42	0.76	0.58	0.43	0.74	-0.36	0.16	0.19	0.75	0.76	-0.39	-0.43	0.2
Short Term Investments	0.92	0.95	0.57	-0.47	-0.03	0.51		0.59	0.91	-0.34	0.17	0.23	0.96	0.56	0.06	0.76	0.42	-0.28	0.41	0.76	0.47	0.48	0.38	0.33	-0.3
Total Liab	0.69	0.55	0.06	0.2	-0.74	0.76	0.59		0.56	0.43	0.76	0.79	0.52	0.91	0.62	0.49	0.91	-0.37	0.15	0.24	0.91	0.92	-0.44	-0.47	0.46
Total Current Assets	0.95	0.98	0.68	-0.65	-0.04	0.46	0.91	0.56		-0.29	0.25	0.31	0.98	0.6	0.06	0.8	0.42	-0.38	0.5	0.76	0.54	0.55	0.32	0.29	-0.22
Short Term Debt	-0.07	-0.29	-0.48	0.71	-0.79	0.31	-0.34	0.43	-0.29		0.8	0.76	-0.36	0.45	0.82	0.02	0.53	0.04	0.07	-0.35	0.5	0.47	-0.9	-0.89	0.74
Common Stock	0.45	0.24	-0.05	0.37	-0.92	0.6	0.17	0.76	0.25	0.8		0.9	0.16	0.8	0.83	0.4	0.87	-0.35	0.24	0.03	0.84	0.81	-0.79	-0.81	0.63
Property Plant Equipment	0.52	0.3	-0.06	0.36	-0.81	0.49	0.23	0.79	0.31	0.76	0.9		0.25	0.78	0.85	0.37	0.78	-0.2	0.19	0.16	0.83	0.8	-0.66	-0.69	0.63
Net Tangible Assets	0.94	0.99	0.65	-0.62	0.04	0.42	0.96	0.52	0.98	-0.36	0.16	0.25		0.55	0.04	0.78	0.37	-0.3	0.48	0.85	0.46	0.48	0.41	0.37	-0.29
Long Term Debt	0.7	0.59	0.08	0.06	-0.74	0.76	0.56	0.91	0.6	0.45	0.8	0.78	0.55		0.62	0.55	0.94	-0.37	0.24	0.38	0.97	0.97	-0.47	-0.51	0.42
Net Receivables	0.31	0.09	-0.19	0.54	-0.77	0.58	0.06	0.62	0.06	0.82	0.83	0.85	0.04	0.62		0.25	0.65	-0.06	0.19	0.07	0.66	0.62	-0.71	-0.74	0.68
Good Will	0.84	0.83	0.5	-0.44	-0.13	0.43	0.76	0.49	0.8	0.02	0.4	0.37	0.78	0.55	0.25		0.4	-0.28	0.87	0.64	0.43	0.43	0.14	0.12	-0.13
Capital Surpluse	0.55	0.41	-0.01	0.25	-0.89	0.74	0.42	0.91	0.42	0.53	0.87	0.78	0.37	0.94	0.65	0.4		-0.52	0.1	0.16	0.95	0.95	-0.64	-0.68	0.54
Deferred Long Term Liab	-0.32	-0.32	-0.46	0.25	0.37	-0.36	-0.28	-0.37	-0.38	0.04	-0.35	-0.2	-0.3	-0.37	-0.06	-0.28	-0.52		-0.14	-0.02	-0.45	-0.47	0.2	0.23	-0.13
Intangible Assets	0.51	0.54	0.41	-0.41	0.07	0.16	0.41	0.15	0.5	0.07	0.24	0.19	0.48	0.24	0.19	0.87	0.1	-0.14		0.47	0.12	0.11	0.17	0.17	-0.06
Long Term Investments	0.75	0.84	0.52	-0.55	0.19	0.19	0.76	0.24	0.76	-0.35	0.03	0.16	0.85	0.38	0.07	0.64	0.16	-0.02	0.47		0.23	0.25	0.46	0.41	-0.32
Long Term Debt Total	0.64	0.5	0.07	0.12	-0.82	0.75	0.47	0.91	0.54	0.5	0.84	0.83	0.46	0.97	0.66	0.43	0.95	-0.45	0.12	0.23		1.0	-0.56	-0.6	0.49
Short Long Term Debt	0.64	0.51	0.09	0.1	-0.8	0.76	0.48	0.92	0.55	0.47	0.81	0.8	0.48	0.97	0.62	0.43	0.95	-0.47	0.11	0.25	1.0		-0.54	-0.57	0.48
Net Invested Capital	0.14	0.35	0.51	-0.7	0.91	-0.39	0.38	-0.44	0.32	-0.9	-0.79	-0.66	0.41	-0.47	-0.71	0.14	-0.64	0.2	0.17	0.46	-0.56	-0.54		1.0	-0.71
Net Working Capital	0.1	0.31	0.47	-0.7	0.92	-0.43	0.33	-0.47	0.29	-0.89	-0.81	-0.69	0.37	-0.51	-0.74	0.12	-0.68	0.23	0.17	0.41	-0.6	-0.57	1.0		-0.71
Capital Stock	-0.1	-0.25	-0.35	0.58	-0.67	0.2	-0.3	0.46	-0.22	0.74	0.63	0.63	-0.29	0.42	0.68	-0.13	0.54	-0.13	-0.06	-0.32	0.49	0.48	-0.71	-0.71

Click cells to compare fundamentals

About Bluebird Bio Financial Statements

Bluebird Bio stakeholders use historical fundamental indicators, such as Bluebird Bio's Net Debt, to determine how well the company is positioned to perform in the future. Although Bluebird Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bluebird Bio's assets and liabilities are reflected in the revenues and expenses on Bluebird Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bluebird bio. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	193.6 M	203.3 M
Net Debt To EBITDA	(0.65)	(0.62)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:

How To Invest In Bluebird

Details

Is Bluebird Stock a good investment?

Details

What is Bluebird Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Bluebird Bio Correlation against competitors.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.80)

Revenue Per Share

0.357

Quarterly Revenue Growth

1.337

Return On Assets

(0.36)

Return On Equity

(1.87)

The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bluebird Net Debt from 2010 to 2024

Latest Bluebird Bio's Net Debt Growth Pattern

Bluebird Net Debt Regression Statistics

Bluebird Net Debt History

Other Fundumenentals of Bluebird bio

Bluebird Bio Net Debt component correlations

About Bluebird Bio Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY